Datapoint: FDA Approves Jemperli as Frontline Endometrial Cancer Treatment

August 7

The FDA on July 31 approved GSK’s Jemperli for the treatment of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer in adult patients who are also receiving chemotherapy. Notably, the drug beat out fellow PD-1 inhibitor Keytruda, which is still awaiting a first-line endometrial cancer decision from the FDA. Jemperli was first approved in April 2021 to treat dMMR recurrent or advanced endometrial cancer in patients that have already received platinum-based chemotherapy. It currently holds covered or better status for 88% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 8/2/23